Cargando…

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch

BACKGROUND: Antispike monoclonal antibodies are recommended for early treatment of high-risk persons with mild to moderate coronavirus disease 2019 (COVID-19). However, clinical outcomes of their use during the severe acute respiratory syndrome coronavirus 2 Omicron wave are limited. METHODS: This i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Razonable, Raymund R, Tulledge-Scheitel, Sidna M, Hanson, Sara N, Arndt, Richard F, Speicher, Leigh L, Seville, Teresa A, Larsen, Jennifer J, Ganesh, Ravindra, O’Horo, John C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536189/ https://www.ncbi.nlm.nih.gov/pubmed/36213724 http://dx.doi.org/10.1093/ofid/ofac411

Ejemplares similares

518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge
por: Chesdachai, Supavit, et al.
Publicado: (2023)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
por: O’Horo, John C., et al.
Publicado: (2022)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
por: Yetmar, Zachary A, et al.
Publicado: (2021)

Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era
por: McCreary, Erin K, et al.
Publicado: (2022)

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
por: Yetmar, Zachary A, et al.
Publicado: (2022)

Patient Satisfaction With Providers: Do Patient Surveys Give Enough Information to Help Providers Improve Specific Behaviors
por: North, Frederick, et al.
Publicado: (2019)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
por: Johnson, Patrick W., et al.
Publicado: (2023)

Association of provider opioid prescribing practices and the Centers for Medicare and Medicaid Services hierarchical condition category score: A retrospective examination of correlation between the volume of provider-prescribed opioid medications and provider panel complexity
por: North, Frederick, et al.
Publicado: (2017)

Do primary care providers who prescribe more opioids have higher patient panel satisfaction scores?
por: North, Frederick, et al.
Publicado: (2018)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
por: Alcantara, Mellissa C., et al.
Publicado: (2023)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Cryptococcus Species Other Than Cryptococcus neoformans and Cryptococcus gattii: Are They Clinically Significant?
por: Cano, Edison J, et al.
Publicado: (2020)

Bebtelovimab-Induced Bradycardia Leading to Cardiac Arrest
por: Gearges, Christina, et al.
Publicado: (2022)

Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity
por: Kirisri, Similan, et al.
Publicado: (2021)

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
por: Hentzien, Maxime, et al.
Publicado: (2022)

Is a switch to a different electronic health record associated with a change in patient satisfaction?
por: North, Frederick, et al.
Publicado: (2020)

290. Hepatitis E Virus Serostatus: A Retrospective Assessment of Demographics and Comorbidities to Assess High-risk Populations
por: Stone, Eric C, et al.
Publicado: (2019)

Use of a Web-based clinical decision support system to improve abdominal aortic aneurysm screening in a primary care practice
por: Chaudhry, Rajeev, et al.
Publicado: (2012)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5
por: Molina, Kyle C., et al.
Publicado: (2023)

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023)

Effect of visit length and a clinical decision support tool on abdominal aortic aneurysm screening rates in a primary care practice
por: Eaton, John, et al.
Publicado: (2012)

Population health challenges in primary care: What are the unfinished tasks and who should do them?
por: North, Frederick, et al.
Publicado: (2018)

The Diagnostic Accuracy of Metagenomic Next-Generation Sequencing in Diagnosing Pneumocystis Pneumonia: A Systemic Review and Meta-analysis
por: Tekin, Aysun, et al.
Publicado: (2023)

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial
por: Shapiro, Adrienne E, et al.
Publicado: (2023)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Comparison of Standardized Cytomegalovirus (CMV) Viral Load Thresholds in Whole Blood and Plasma of Solid Organ and Hematopoietic Stem Cell Transplant Recipients with CMV Infection and Disease
por: Dioverti, M Veronica, et al.
Publicado: (2017)

Left Ventricular Assist Device: Review of Antimicrobial Prophylaxis Strategies and Incidence of Infections at a Tertiary Care Center 12-Year Experience
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

A Retrospective Analysis of Provider-to-Patient Secure Messages: How Much Are They Increasing, Who Is Doing the Work, and Is the Work Happening After Hours?
por: North, Frederick, et al.
Publicado: (2020)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4m7blbjomikuds2tsv1d5gglpm